Improved adeno-associated virus vector design and manufacturability can enhance the efficacy of gene therapies for atrial cardiomyopathy.
Gene therapies using adeno-associated virus vectors offer a potential root-cause treatment for atrial cardiomyopathy, though improvements in vector design and manufacturability are needed.
Absolute Event Rate: 0% vs 0%
Gene therapies provide an opportunity to treat ACM at the root cause beyond the management of its sequelae. However, solutions aiming to improve vector design, manufacturability and suitability for ACM should be adopted to improve therapeutic efficacy and broaden patient accessibility.
Hammoud et al. (Sat,) reported a other. Improved adeno-associated virus vector design and manufacturability can enhance the efficacy of gene therapies for atrial cardiomyopathy.